Conference: CiMUS Innopharma Open Innovation Day
CiMUS Innopharma Open Innovation Day, Santiago de Compostela, Spain Stefan Senger (GlaxoSmithKline) gave a presentation: What is Open PHACTS and why would you care?
Presentation: What is Open PHACTS and why would you care?
CiMUS Innopharma Open Innovation Day, Santiago de Compostela, Spain Stefan Senger (GlaxoSmithKline) View presentation
Open PHACTS project extended for another 18 months
We are delighted to announce that the Open PHACTS project will be extendedfor 18 months until the end of February 2016. For the extension two new partners – Laboratorios Almirall S.A. and SciBite Limited – will join the consortium and GlaxoSmithKline (GSK) will act as coordinator.
Press Release: Open PHACTS Foundation announces first three members: GSK, Janssen and Roche
(PDF) Cambridge, UK – The not-for-profit Open PHACTS Foundation announced its first three members today – GlaxoSmithKline, Janssen and Roche – who will steer the future of the successor organisation to the Innovative Medicines Initiative (IMI)- funded Open PHACTS project. The commitment by these global pharmaceutical industry members signifies a major…
Presentation: Open PHACTS: Data integration for all
14th Annual Drug Discovery Summit, Geneva, Switzerland Andrew Leach (GlaxoSmithKline) View presentation
Conference: 14th Annual Drug Discovery Summit
14th Annual Drug Discovery Summit, Geneva, Switzerland Andrew Leach (GlaxoSmithKline) gave a presentation: Open PHACTS: Data integration for all
Conference: Advances and Progress in Drug Design 2013
SMi Annual Advances and Progress in Drug Design 2013, London, UK Andrew Leach (GlaxoSmithKline) gave a presentation
Publication: Druggable and biopharmable genome annotation pipeline development
The identification of proteins which could be potential targets for new pharmaceutical products is invaluable for the continued improvement people’s quality of life and expansion of available treatment options. In order to aid the discovery of new drug targets, predictions of every human gene likely to be exploitable by compounds…